Johnson Investment Counsel Inc. Buys 7,603 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Johnson Investment Counsel Inc. raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 34.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,428 shares of the medical instruments supplier's stock after buying an additional 7,603 shares during the quarter. Johnson Investment Counsel Inc. owned about 0.13% of LeMaitre Vascular worth $2,469,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $14,900,000. Rockefeller Capital Management L.P. bought a new position in LeMaitre Vascular in the 4th quarter valued at approximately $7,787,000. Segall Bryant & Hamill LLC purchased a new stake in LeMaitre Vascular during the 4th quarter valued at $5,446,000. Invesco Ltd. increased its holdings in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of LeMaitre Vascular by 7,486.5% in the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock worth $4,519,000 after purchasing an additional 53,154 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 18,733 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the sale, the chief executive officer now owns 1,873,651 shares of the company's stock, valued at approximately $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 100,000 shares of company stock valued at $8,556,857. 9.50% of the stock is owned by company insiders.

LeMaitre Vascular Stock Up 0.1%

LeMaitre Vascular stock opened at $81.78 on Friday. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The stock has a fifty day moving average of $83.84 and a 200 day moving average of $89.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.83 and a current ratio of 16.49. The stock has a market cap of $1.85 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 2.16 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The business had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. During the same period in the previous year, the company earned $0.44 EPS. LeMaitre Vascular's revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.98%. LeMaitre Vascular's dividend payout ratio (DPR) is 40.40%.

Analysts Set New Price Targets

Several equities research analysts recently commented on LMAT shares. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Lake Street Capital raised their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $97.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.